HK Stock Market Move | HUTCHMED (00013) Rises Over 4% Again, Up Over 20% This Month. SACHI Phase III Study Results Published in The Lancet.

HUTCHMED (00013) has risen by over 4%, with a cumulative increase of over 20% this month. As of the time of writing, it has increased by 3.68% to HK$24.8, with a trading volume of HK$1.42 billion. On the news front, HUTCHMED announced that the results of the SACHI III study have been published in The Lancet. SACHI is a combination therapy of savolitinib and osimertinib for the treatment of stage III patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer with MET amplification after first-line EGFR TKI therapy progression. Savolitinib is a potent, highly selective oral MET TKI developed jointly by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca. Osimertinib is an irreversible third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.